Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD9X | ISIN: US92829J1043 | Ticker-Symbol:
NASDAQ
19.04.24
15:30 Uhr
0,459 US-Dollar
+0,010
+2,20 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIOS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VIRIOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.03.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID200- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally - - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation...
► Artikel lesen
08.03.Virios Therapeutics, Inc. - 10-K/A, Annual Report1
06.03.Virios Therapeutics, Inc. - 8-K, Current Report1
01.03.Virios Therapeutics reports Q4 results1
01.03.Virios Therapeutics, Inc. - 10-K, Annual Report2
29.02.Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results550ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
► Artikel lesen
28.02.Virios Therapeutics plans shareholder meeting on stock split1
28.02.Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones429ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
► Artikel lesen
27.02.Virios Therapeutics announces salary cuts for employees and board2
27.02.Virios Therapeutics, Inc. - 8-K, Current Report1
22.01.Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID598- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics...
► Artikel lesen
03.01.Virios Therapeutics, Inc. - 8-K, Current Report2
02.01.Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2-
02.01.Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID232ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on developing novel antiviral therapies to treat...
► Artikel lesen
13.11.23Virios Therapeutics Inc reports results for the quarter ended in September - Earnings Summary2
13.11.23Virios Therapeutics, Inc. - 10-Q, Quarterly Report-
13.11.23Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update229- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on...
► Artikel lesen
11.11.23Virios Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview1
10.11.23Virios Therapeutics' Earnings Outlook1
07.11.23Virios Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1